Derrick Welsh - Revive Therapeutics COO Pharma

All Insiders . USA . 
Stock . Revive Therapeutics . Stakeholders . Insider . Derrick Welsh
RVVTF Stock  USD 0.01  0.0009  12.86%   

Insider

Derrick Welsh is COO Pharma of Revive Therapeutics
Phone888 901 0036
Webhttps://www.revivethera.com

Revive Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.4252) % which means that it has lost $0.4252 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8286) %, meaning that it generated substantial loss on money invested by shareholders. Revive Therapeutics' management efficiency ratios could be used to measure how well Revive Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Revive Therapeutics has accumulated 60 K in total debt with debt to equity ratio (D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Revive Therapeutics has a current ratio of 1.79, which is within standard range for the sector. Debt can assist Revive Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Revive Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Revive Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Revive to invest in growth at high rates of return. When we think about Revive Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Stephan BankoszVext Science
N/A
Ivana MaricAvicanna
N/A
Caitlin JohnstonAvicanna
N/A
Frantz DevedecAvicanna
N/A
Jakob FeinsteinCuraleaf Holdings
N/A
Edward KremerCuraleaf Holdings
51
Swadheen SehgalGreen Thumb Industries
N/A
Christine HerseyTrulieve Cannabis Corp
N/A
James ShorrisCuraleaf Holdings
61
Nilyum JhalaTrulieve Cannabis Corp
N/A
Camilo LyonCuraleaf Holdings
N/A
Joe HollandCuraleaf Holdings
N/A
Robert KremerTrulieve Cannabis Corp
N/A
Roland AlvarezAvicanna
N/A
Rebecca YoungTrulieve Cannabis Corp
42
Jason NguyenVext Science
N/A
Mba BEconAvicanna
N/A
Jason PernellTrulieve Cannabis Corp
45
Kimberly RiversTrulieve Cannabis Corp
45
Steven WhiteTrulieve Cannabis Corp
49
Mathew FaulknerGreen Thumb Industries
50
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company was incorporated in 2012 and is headquartered in Toronto, Canada. Revive Therapeutics is traded on OTC Exchange in the United States. Revive Therapeutics [RVVTF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-0.83
Return On Asset-0.43

Revive Therapeutics Leadership Team

Elected by the shareholders, the Revive Therapeutics' board of directors comprises two types of representatives: Revive Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revive. The board's role is to monitor Revive Therapeutics' management team and ensure that shareholders' interests are well served. Revive Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revive Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Frank, Chairman CEO
Derrick Welsh, COO Pharma
Onesmo Mpanju, Chief Consultant
ACIS BComm, Chief Officer
McKee MD, Chief Consultant

Revive Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Revive Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.83
Return On Asset-0.43
Current Valuation32.12 M
Shares Outstanding353.56 M
Shares Owned By Insiders2.48 %
Shares Owned By Institutions2.42 %
Price To Earning(4.10) X
Price To Book4.00 X
EBITDA(17.74 M)
Net Income(17.81 M)

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Revive OTC Stock

Revive Therapeutics financial ratios help investors to determine whether Revive OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Revive with respect to the benefits of owning Revive Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY